Caroline M A van den Bosch1, Marlies E J L Hulscher2, Reinier P Akkermans2, Jan Wille3, Suzanne E Geerlings1, Jan M Prins1. 1. Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, The Netherlands. 2. Department of Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. 3. Department of Center for Infectious Diseases, Epidemiology and Surveillance, The National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Abstract
Objectives: To define appropriate antibiotic use in hospitalized adults treated for a bacterial infection, we previously developed and validated a set of six generic quality indicators (QIs) covering all steps in the process of antibiotic use. We assessed the association between appropriate antibiotic use, defined by these QIs, and length of hospital stay (LOS). Methods: An observational multicentre study in 22 hospitals in the Netherlands included 1890 adult, non-ICU patients using antibiotics for a suspected bacterial infection. Performance scores were calculated for all QIs separately (appropriate or not), and a sum score described performance on the total set of QIs. We divided the sum scores into two groups: low (0%-49%) versus high (50%-100%). Multilevel analyses, correcting for confounders, were used to correlate QI performance (single and combined) with (log-transformed) LOS and in-hospital mortality. Results: The only single QI associated with shorter LOS was appropriate intravenous-oral switch (geometric means 6.5 versus 11.2 days; P < 0.001). A high sum score was associated with a shorter LOS in the total group (10.1 versus 11.2 days; P = 0.002) and in the subgroup of community-acquired infections (9.7 versus 10.9 days; P = 0.007), but not in the subgroup of hospital-acquired infections. We found no association between performance on QIs and in-hospital mortality or readmission rate. Conclusions: Appropriate antibiotic use, defined by validated process QIs, in hospitalized adult patients with a suspected bacterial infection appears to be associated with a shorter LOS and therefore positively contributes to patient outcome and healthcare costs.
Objectives: To define appropriate antibiotic use in hospitalized adults treated for a bacterial infection, we previously developed and validated a set of six generic quality indicators (QIs) covering all steps in the process of antibiotic use. We assessed the association between appropriate antibiotic use, defined by these QIs, and length of hospital stay (LOS). Methods: An observational multicentre study in 22 hospitals in the Netherlands included 1890 adult, non-ICU patients using antibiotics for a suspected bacterial infection. Performance scores were calculated for all QIs separately (appropriate or not), and a sum score described performance on the total set of QIs. We divided the sum scores into two groups: low (0%-49%) versus high (50%-100%). Multilevel analyses, correcting for confounders, were used to correlate QI performance (single and combined) with (log-transformed) LOS and in-hospital mortality. Results: The only single QI associated with shorter LOS was appropriate intravenous-oral switch (geometric means 6.5 versus 11.2 days; P < 0.001). A high sum score was associated with a shorter LOS in the total group (10.1 versus 11.2 days; P = 0.002) and in the subgroup of community-acquired infections (9.7 versus 10.9 days; P = 0.007), but not in the subgroup of hospital-acquired infections. We found no association between performance on QIs and in-hospital mortality or readmission rate. Conclusions: Appropriate antibiotic use, defined by validated process QIs, in hospitalized adult patients with a suspected bacterial infection appears to be associated with a shorter LOS and therefore positively contributes to patient outcome and healthcare costs.
Authors: Jacqueline T Bork; Kimberly C Claeys; Emily L Heil; Mary Banoub; Surbhi Leekha; John D Sorkin; Michael Kleinberg Journal: Antimicrob Agents Chemother Date: 2020-07-22 Impact factor: 5.191
Authors: M C Kallen; M E J L Hulscher; B Elzer; S E Geerlings; P D van der Linden; S Teerenstra; S Natsch; B C Opmeer; J M Prins Journal: J Antimicrob Chemother Date: 2021-05-12 Impact factor: 5.790
Authors: Frederike V van Daalen; Marlies E J L Hulscher; Cas Minderhoud; Jan M Prins; Suzanne E Geerlings Journal: BMC Infect Dis Date: 2018-01-08 Impact factor: 3.090
Authors: Saskia J Bogers; Frederike V van Daalen; Sacha D Kuil; Menno D de Jong; Suzanne E Geerlings Journal: Eur J Clin Microbiol Infect Dis Date: 2019-03-07 Impact factor: 3.267
Authors: Marvin A H Berrevoets; Jaap Ten Oever; Jacobien Hoogerwerf; Bart Jan Kullberg; Femke Atsma; Marlies E Hulscher; Jeroen A Schouten Journal: JAC Antimicrob Resist Date: 2019-11-13
Authors: Bongyoung Kim; Myung Jin Lee; Se Yoon Park; Song Mi Moon; Kyoung-Ho Song; Tae Hyong Kim; Eu Suk Kim; Hong Bin Kim Journal: Antimicrob Resist Infect Control Date: 2021-03-06 Impact factor: 4.887